Pfizer Inc. (PFE)

39.42
0.44 1.13
NYSE
Prev Close 38.98
Open 39.09
Day Low/High 38.88 / 39.64
52 Wk Low/High 34.32 / 46.47
Volume 25.26M
Exchange NYSE
Shares Outstanding 5551.81B
Market Cap 218.63B
Div & Yield N.A. (N.A)
Pfizer And Lilly Announce Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis

Pfizer And Lilly Announce Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.

Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders

Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders

Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Pfizer Announces Presentation Of Data From A Phase 2 Study Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Announces Presentation Of Data From A Phase 2 Study Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Inc. (NYSE: PFE) announced today the presentation of data from a Phase 2 study of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by...

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.

U.S. FDA Approves IBRANCE® (palbociclib) For The Treatment Of Men With HR , HER2- Metastatic Breast Cancer

U.S. FDA Approves IBRANCE® (palbociclib) For The Treatment Of Men With HR , HER2- Metastatic Breast Cancer

Pfizer (NYSE:PFE) today announced that the U.S.

AM Best Affirms Credit Ratings Of Blue Whale Re Ltd.

AM Best Affirms Credit Ratings Of Blue Whale Re Ltd.

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" of Blue Whale Re Ltd.

VIZIMPRO® (dacomitinib) Receives Marketing Authorization In European Union (EU) For The First-Line Treatment Of Adult Patients With EGFR-Mutated Non-Small Cell Lung Cancer

VIZIMPRO® (dacomitinib) Receives Marketing Authorization In European Union (EU) For The First-Line Treatment Of Adult Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO ® (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell...

Citigroup Is Only One of 46 Companies to Get an 'A' in Equal Pay Day Survey

Citigroup Is Only One of 46 Companies to Get an 'A' in Equal Pay Day Survey

Half of the world's largest corporations receive a failing grade in the Arjuna Capital/Proxy Impact report.

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

- Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc.

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer pays $51 million up front for a 15% stake in French biopharmaceutical company Vivet.

Pfizer Secures Exclusive Option To Acquire Gene Therapy Company Vivet Therapeutics

Pfizer Secures Exclusive Option To Acquire Gene Therapy Company Vivet Therapeutics

Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc.

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc.

Pfizer Invites Public To View And Listen To Webcast Of April 30 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of April 30 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Using Technical Analysis: Cramer's 'Mad Money' Recap (Monday 3/18/19)

Using Technical Analysis: Cramer's 'Mad Money' Recap (Monday 3/18/19)

Jim Cramer explains the art and science of technical analysis.

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb- Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary...

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #14 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #258 spot.

U.S. FDA Approves Pfizer's Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), A Biosimilar To Herceptin®1

U.S. FDA Approves Pfizer's Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), A Biosimilar To Herceptin®1

Pfizer Inc. (NYSE: PFE) today announced the United States (U.

Could Kroger Lose the Grocery Wars Over This Challenge?

Could Kroger Lose the Grocery Wars Over This Challenge?

Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.

Dow Ends Lower as Investors Eye Details From Trade Talks, Oil Prices Tumble

Dow Ends Lower as Investors Eye Details From Trade Talks, Oil Prices Tumble

The Dow Jones Industrial Average ended the day lower as details over the trade talks between the U.S. and China are awaited and oil prices tumble.

AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes

AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes

CAMBRIDGE, Mass., March 5, 2019 /PRNewswire/ -- AnTolRx, Inc.

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Chief Development Officer, Oncology, at the Cowen and Company 39 th Annual Healthcare...

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of five tranches of notes: $500,000,000 aggregate principal amount of 2.

Pfizer Receives Positive CHMP Opinion For LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Receives Positive CHMP Opinion For LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for LORVIQUA ® (lorlatinib, approved in the U.

Pfizer Becomes #1 Most Shorted Dow Stock, Replacing Walgreens Boots Alliance

Pfizer Becomes #1 Most Shorted Dow Stock, Replacing Walgreens Boots Alliance

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Rating: B (Buy)